Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action

Hospital trade groups have lodged strong objections to CMS's proposal to maintain deep Medicare Part B reimbursement cuts, while PhRMA is suggesting even further 340B reforms.

Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B drug reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand

Read More »

Breaking News

Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts

HRSA has referred six drug manufacturers to the HHS Office of Inspector General for refusing to offer 340B discounts in the contract pharmacy setting.

The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered

Read More »

House GOP Effort to Amend 340B Falls Short in Key Committee

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to crucial budget legislation.

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to budget legislation integral to enacting congressional Democrats and the Biden administration’s Build Back Better plan.

The amendments that the House Republicans filed

Read More »

Judge Schedules Joint Hearing in Novartis and United Therapeutics’ 340B Contract Pharmacy Cases

U.S. District Judge Dabney Friedrich scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

A federal district judge in Washington, D.C., yesterday scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

U.S. District Judge Dabney Friedrich is assigned to both cases. In

Read More »

Sanofi Reaches Out to 340B Entities that Complained to HRSA About its Contract Pharmacy Restrictions

Sanofi has sent letters to 340B covered entities that have complained to HRSA about the drug manufacturer's denials of 340B pricing on drugs shipped to contract pharmacies.

Drug manufacturer Sanofi has sent letters to 340B covered entities that have complained to federal authorities about its denials of 340B pricing on drugs shipped to contract pharmacies, covered entity representatives say.

Sanofi has acknowledged but not responded to requests

Read More »

Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule

Former President Trump signed an executive order in July 2020 directing HHS to limit what 340B health centers can charge patients for insulin and EpiPen-type devices.

The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.

Late last week Thursday, the U.S. Health Resources

Read More »

U.S. Supreme Court Gets Several Briefs Urging Rejection of CMS’s Drug Payment Cuts for 340B Hospitals

Nine friend-of-the-court briefs have been filed urging the U.S. Supreme Court to strike down the CMS rule that imposed a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.

Nine friend-of-the-court briefs have been filed in the nation’s highest court urging rejection of an appeals court’s decision last year that upheld a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.

Thirty-seven state and regional hospital associations

Read More »

Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug

Napo Pharmaceuticals has told covered entities how they can continue to buy Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs, at its 340B price.

Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.

Napo said in the notice on the U.S. Health

Read More »

News Alert: Key House Committee Excludes “Spread Pricing” Language that 340B Entities Feared from Drug Pricing Legislation

The House Energy & Commerce Committee excluded spread-pricing language that 340B entities feared from forthcoming drug pricing legislation.

340B covered entities are breathing easier today upon learning that U.S. House Democrats excluded much-feared Medicaid managed care “spread pricing” language from forthcoming drug pricing legislation.

The House Energy & Commerce Committee late yesterday released the text of the 16

Read More »

In Largely Symbolic Move, Becerra Expresses “Strong Support” for 340B in Drug Pricing Plan

HHS Secretary Xavier Becerra yesterday expressed "strong support" for the 340B program in a drug pricing report to the White House, but recommended no changes to the program.

U.S. Health and Human Services Secretary Xavier Becerra yesterday reiterated HHS’ “strong support for the 340B Drug Pricing Program” in a 29-page plan to lower drug prices.

Becerra’s Sept. 9 report to White House domestic and economic policy counselors

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report